Table 3 Comparison of our model-based predictions of cure rates with observational data.

From: Improving treatment outcome assessment in a mouse tuberculosis model

 

Regimen

% cured at:

Ref.

3 months

4 months

5 months

Our model BALB/c, Beijing, HDIT

2 RpZHE/1,2,3 RpHa

62%

97%

100%

 

2 RZME/1,2,3 RMa

60%

97%

100%

 

2 RZMH/1,2,3 RMHa

2%

29%

81%

 

Model 1 BALB/c, H37Rv, HDA

2 RpZM/1,2 RpM

100%

  

22

3,4,5 RZM

75%

100%

100%

5

2 RZM/1,2,3 RM

83%

100%

100%

5

2 RZM/2,3 RM

 

95%

100%

23

Model 2 BALB/c, H37Rv, LDA

2 RZME/1 RM

80%

  

12

2 RZMH/1 RMH

27%

  

12

Model 3 BALB/c, Erdman, HDA

2 RZM/2 RM

 

84%

 

13

Model 4 BALB/c, Erdman, LDA

3 RZME

100%

  

12

3 RZMH

93%

  

12

2 RZM/1 RM, 2 RM

100%

95%

 

13

Model 5 C3HeB/FeJb, H37Rv, LDA

2 RZME/1 RM

80%

  

12

2 RZMH/1 RMH

80%

  

12

Model 6 C3HeB/FeJb, Erdman, LDA

3 RZME

40%

  

12

3 RZMH

0%

  

12

  1. aPredicted cure for 3,4 and 5 months of treatment is shown as estimated in Fig. 3, bC3HeB/FeJ mice can develop cavitating lesions that more closely resemble human disease, Abbreviations for route of infection: HDIT = high dose intratracheally, HDA = high dose aerosol, LDA = low dose aerosol, R = rifampicin, Rp = rifapentine, Z = pyrazinamide, M = moxifloxacin, H = isoniazid, E = Ethambutol.
Back to article page